# Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine

> **NCT01405677** · PHASE2 · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 308 (actual)

## Conditions studied

- Hepatitis A

## Interventions

- **BIOLOGICAL:** Epaxal 0.25 mL
- **BIOLOGICAL:** Epaxal 0.5 mL
- **BIOLOGICAL:** Havrix Junior 0.5 mL

## Key facts

- **NCT ID:** NCT01405677
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2014-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01405677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01405677, "Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01405677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*